Related Experiment Video
Updated: Jun 12, 2025
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Severe respiratory syncytial virus disease
Yolanda Peña-López1,2,3, Joan Sabater-Riera4,5, Prithvi Raj1
1Microbiome Research Laboratory (MRL), Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Insights
Respiratory syncytial virus (RSV) causes significant disease, especially in vulnerable populations. Current treatments are supportive, but new antivirals and vaccines show future promise for managing severe RSV infections.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pulmonology
Background:
- Respiratory syncytial virus (RSV) poses a substantial global health burden, particularly affecting infants, the elderly, and immunocompromised individuals.
- Severe RSV disease disproportionately impacts hospitalized adults with comorbidities, necessitating intensive care.
- Current management relies heavily on supportive care, highlighting the need for advanced therapeutic strategies.
Purpose of the Study:
- To review the current understanding of respiratory syncytial virus (RSV) disease burden, risk factors, and management strategies.
- To discuss advancements in supportive care for severe RSV infections, including ventilation techniques.
- To explore the challenges and future directions in treating RSV, including bacterial co-infections and novel therapeutics.
Main Methods:
- Literature review of existing studies on respiratory syncytial virus (RSV) epidemiology, clinical presentation, and treatment modalities.
- Analysis of current clinical practices for managing severe RSV disease in pediatric and adult populations.
- Examination of emerging evidence on antiviral therapies, vaccines, and passive immunization strategies.
Main Results:
- Severe RSV disease management has benefited from non-invasive ventilation and high-flow oxygen, particularly in children.
- Refractory hypoxemia in severe cases often requires advanced support like mechanical ventilation or ECMO.
- Bacterial co-infections, though infrequent, are linked to poorer outcomes, posing diagnostic challenges and complicating antibiotic stewardship.
Conclusions:
- While supportive care remains central, advancements in ventilation and oxygenation have improved outcomes for severe RSV.
- Accurate diagnosis of bacterial co-infections is crucial but challenging, necessitating judicious antibiotic use.
- The future of RSV treatment hinges on the successful development and implementation of novel antiviral therapies, vaccines, and passive immunization strategies like nirsevimab.
Abstract:
The burden of respiratory syncytial virus (RSV) disease is widely recognized. Main risk factors for severe disease, such as extreme ages, chronic cardiopulmonary conditions, and immunosuppression, typically coincide with poorer outcomes. While the majority of RSV hospitalizations involve healthy children, a higher proportion of hospitalized adults with underlying conditions need intensive care. Presently, treatment primarily consists of supportive measures. RSV-induced wheezing should be distinguished from respiratory tract thickening, without response to bronchodilators. Obstructive RSV disease frequently overlaps with viral pneumonia. Non-invasive mechanical ventilation and high-flow oxygen therapy represented significant advancements in the management of severe RSV disease in children and may also hold considerable importance in specific phenotypes of RSV disease in adults. Most severe infections manifest with refractory hypoxemia necessitating more advanced ventilatory support and/or extracorporeal membrane oxygenation therapy. Although bacterial co-infection rates are low, they have been associated with worse outcomes. Antibiotic prescription rates are high. Accurately diagnosing bacterial co-infections remains a challenge. Current evidence and antibiotic stewardship policies advise against indiscriminate antibiotic usage, even in severe cases. The role of currently developing antiviral therapies in severe RSV disease will be elucidated in the coming years, contingent upon the success of new vaccines and immune passive strategies involving nirsevimab.
Related Concept Videos
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:21Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
01:30Acute Respiratory Failure-III
01:23Acute Respiratory Failure-IV